Holen Sie sich die Stockscreener-App
12.38
4.43%
0.5299
Schlusskurs vom Vortag:
$11.85
Offen:
$11.97
24-Stunden-Volumen:
63,534
Relative Volume:
0.31
Marktkapitalisierung:
$471.43M
Einnahmen:
$239.40M
Nettoeinkommen (Verlust:
$104.44M
KGV:
4.1824
EPS:
2.96
Netto-Cashflow:
$-18.50M
1W Leistung:
+3.30%
1M Leistung:
+14.37%
6M Leistung:
+137.07%
1J Leistung:
+12.60%
1-Tages-Spanne:
$11.75
$12.35
1-Wochen-Bereich:
$11.21
$12.93
52-Wochen-Spanne:
$4.93
$12.93
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Firmenname
Entrada Therapeutics Inc
Sektor
Branche
Telefon
857-305-1825
Adresse
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
12.34 | 452.90M | 239.40M | 104.44M | -18.50M | 2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.06 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.44 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.06 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.34 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.90 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-11 | Eingeleitet | Guggenheim | Buy |
| 2026-01-28 | Eingeleitet | Oppenheimer | Outperform |
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2023-04-03 | Eingeleitet | H.C. Wainwright | Buy |
Entrada Therapeutics Inc Aktie (TRDA) Neueste Nachrichten
Entrada Therapeutics (TRDA) CEO gets RSUs, options and tax-related share sales - Stock Titan
Entrada Therapeutics (TRDA) CFO receives new equity grants and automatic tax share sales - Stock Titan
Entrada Therapeutics (TRDA) COO logs new RSU, option grants and tax share disposals - Stock Titan
Entrada Therapeutics (TRDA) grants RSUs and options as automatic share sales cover taxes - Stock Titan
Advancing Exon-Skipping and Undervalued DM1 Collaboration Underscore Buy Rating on Entrada Therapeutics - TipRanks
Entrada Therapeutics Announces Inducement Grants - National Today
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Entrada Therapeutics (NASDAQ:TRDA) Stock Rating Upgraded by Wall Street Zen - Defense World
The Technical Signals Behind (TRDA) That Institutions Follow - Stock Traders Daily
Entrada Therapeutics earnings beat by $0.04, revenue fell short of estimates - Investing.com Canada
Entrada Therapeutics (NASDAQ:TRDA) Posts Earnings Results, Beats Estimates By $0.38 EPS - MarketBeat
Entrada Therapeutics, Inc. (TRDA) Stock Analysis: Exploring A 54% Potential Upside - DirectorsTalk Interviews
Entrada Therapeutics Q4 net loss and EPS beat expectations - TradingView
Earnings Summary: Entrada Therapeutics Q4 - Benzinga
Entrada Therapeutics, Inc. SEC 10-K Report - TradingView
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
Entrada Therapeutics (NASDAQ: TRDA) maps DMD, DM1 and ocular drug pipeline - Stock Titan
Entrada Therapeutics (TRDA) swings to 2025 loss while advancing DMD pipeline - Stock Titan
DMD trials advance as Entrada extends cash runway to Q3 2027 - Stock Titan
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN) and Xenon (XENE) - The Globe and Mail
Duchenne Muscular Dystrophy Clinical Trial Pipeline Gains Momentum: 75+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - StreetInsider
Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock? - MSN
Signal Recap: How does Entrada Therapeutics Inc compare to its peersQuarterly Risk Review & Community Trade Idea Sharing Platform - baoquankhu1.vn
What analysts say about Entrada Therapeutics Inc. stockM&A Rumor & Long-Term Safe Investment Plans - mfd.ru
Entrada Therapeutics’ (TRDA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Entrada Therapeutics, Inc. (TRDA) Stock Analysis: Potential Upside of 67.57% Could Attract Investors - DirectorsTalk Interviews
Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline - Finviz
Entrada Therapeutics (TRDA) to Release Earnings on Thursday - Defense World
EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains? - Yahoo Finance
HC Wainwright & Co. Reiterates Buy Rating on TRDA with $20 PT | - GuruFocus
Market Pulse: Should I trade or invest in Century Therapeutics IncJuly 2025 Big Picture & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study - Bitget
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study - The Manila Times
Duchenne drug trial doubles dose to 12 mg/kg, aims at accelerated FDA approval - Stock Titan
Entrada Therapeutics Teases Data-Rich 2026 With DMD and DM1 Catalysts at Guggenheim Summit - Defense World
Precision Trading with Entrada Therapeutics Inc. (TRDA) Risk Zones - Stock Traders Daily
What are Entrada Therapeutics Inc.’s recent SEC filings showingLayoff News & AI Driven Stock Price Forecasts - mfd.ru
Why analysts remain bullish on Entrada Therapeutics Inc. stockBear Alert & Reliable Price Breakout Alerts - mfd.ru
Will Entrada Therapeutics Inc. stock gain from lower inflationJuly 2025 Patterns & Long-Term Capital Growth Ideas - mfd.ru
Entrada Therapeutics (NASDAQ:TRDA) Raised to Strong-Buy at Guggenheim - MarketBeat
Published on: 2026-02-13 04:19:34 - mfd.ru
Will Entrada Therapeutics Inc. benefit from rising consumer demandMarket Risk Analysis & High Conviction Buy Zone Alerts - mfd.ru
Can Entrada Therapeutics Inc. outperform under higher oil pricesEarnings Growth Summary & Low Risk Entry Point Tips - mfd.ru
This Olema Pharmaceuticals analyst begins coverage on a bullish note; here are top 4 initiations for Wednesday - MSN
Entrada Therapeutics, Inc. (TRDA) Stock Analysis: Exploring A Bold 67% Upside Potential - DirectorsTalk Interviews
TRDA: Q2 data expected to show strong safety and efficacy, de-risking future exon programs - TradingView
TRDA: Multiple clinical milestones in 2024 aim to validate a scalable, differentiated DMD platform - TradingView
Entrada Therapeutics (TRDA): Guggenheim Initiates Coverage With 'Buy' Rating | TRDA Stock News - GuruFocus
This Olema Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Update Recap: How does Entrada Therapeutics Inc compare to its peersGap Down & High Conviction Trade Alerts - baoquankhu1.vn
Finanzdaten der Entrada Therapeutics Inc-Aktie (TRDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):